| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17937291 | IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:20097460 | IVTH | 0.000000001 - 0.00001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000000001 - 0.00001 M | 0.0000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:21251947 | IVR | 5 mg/kg | 5 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| PMID:23050436 | IVR | 1.47 mg/kg | - | No significant effects observed | - |
| IVR | 4.41 mg/kg | 4.41 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 13.2 mg/kg | 13.2 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 13.2 mg/kg | 13.2 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:23994515 | IVR | 15 mg/kg | 15 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 15 mg/kg | 15 mg/kg | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| PMID:24449165 | IVR | 15 mg/kg/day | 15 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations |
| IVR | 15 mg/kg/day | 15 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg/day | 15 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 7.5 mg/kg/day | 7.5 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 7.5 mg/kg/day | 7.5 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 7.5 mg/kg/day | 7.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:24938463 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Alterations in immune responses | Immunological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.